Total Payments
$10,971
2024 Payments
$758.65
Companies
57
Transactions
210
Medicare Patients
5,140
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$7,073 (64.5%)
Consulting$3,150 (28.7%)
Education$709.88 (6.5%)
Travel$37.46 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,073 | 186 | 64.5% |
| Consulting Fee | $3,150 | 4 | 28.7% |
| Education | $709.88 | 19 | 6.5% |
| Travel and Lodging | $37.46 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $3,266 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $549.73 | 29 | $0 (2020) |
| GENZYME CORPORATION | $503.64 | 6 | $0 (2022) |
| Amgen Inc. | $499.66 | 14 | $0 (2022) |
| Merck Sharp & Dohme LLC | $405.91 | 11 | $0 (2022) |
| GlaxoSmithKline, LLC. | $382.97 | 6 | $0 (2022) |
| Genentech USA, Inc. | $354.35 | 10 | $0 (2019) |
| COMSORT, Inc | $350.00 | 3 | $0 (2019) |
| Seattle Genetics, Inc. | $293.23 | 10 | $0 (2019) |
| Abbott Laboratories | $264.96 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $758.65 | 8 | Abbott Laboratories ($165.05) |
| 2023 | $608.19 | 7 | Gilead Sciences, Inc. ($127.29) |
| 2022 | $728.01 | 10 | Amgen Inc. ($124.99) |
| 2021 | $710.16 | 12 | GENZYME CORPORATION ($265.01) |
| 2020 | $281.15 | 12 | Amgen Inc. ($116.15) |
| 2019 | $4,995 | 73 | AstraZeneca Pharmaceuticals LP ($2,940) |
| 2018 | $1,248 | 39 | Seattle Genetics, Inc. ($175.93) |
| 2017 | $1,642 | 49 | Astellas Pharma US Inc ($221.74) |
All Payment Transactions
210 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $43.16 | General |
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $39.77 | General |
| 10/23/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: CELLT | ||||||
| 04/08/2024 | Abbott Laboratories | COROFLOW (Device) | Food and Beverage | In-kind items and services | $165.05 | General |
| Category: Vascular | ||||||
| 04/04/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $129.21 | General |
| Category: Oncology / Rare Diseases | ||||||
| 03/26/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $95.85 | General |
| Category: SURGERY | ||||||
| 02/29/2024 | ERBE USA INC | CRYO2 (Device) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Internal Medicine | ||||||
| 01/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $115.61 | General |
| 10/12/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.30 | General |
| 09/27/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONC | ||||||
| 04/19/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 04/18/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Oncology | ||||||
| 03/16/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Oncology | ||||||
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $114.96 | General |
| Category: Oncology | ||||||
| 02/24/2023 | Abbott Laboratories | OPTIS (Device) | Food and Beverage | In-kind items and services | $99.91 | General |
| Category: Vascular | ||||||
| 11/30/2022 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $98.74 | General |
| Category: Oncology | ||||||
| 09/28/2022 | Ethicon US, LLC | Neuwave (Device) | Food and Beverage | In-kind items and services | $114.74 | General |
| Category: Ablation System | ||||||
| 08/09/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $4.80 | General |
| Category: ONCOLOGY | ||||||
| 06/16/2022 | EISAI INC. | Lenvima (Drug) | Education | Cash or cash equivalent | $21.76 | General |
| Category: Oncology | ||||||
| 06/15/2022 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 05/19/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $111.06 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $95.41 | General |
| Category: Oncology | ||||||
| 01/13/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $25.52 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 991 | 19,067 | $3.5M | $769,270 |
| 2022 | 32 | 1,355 | 36,775 | $1.5M | $417,439 |
| 2021 | 33 | 1,309 | 33,786 | $1.4M | $396,570 |
| 2020 | 33 | 1,485 | 30,270 | $1.9M | $520,912 |
Total Patients
5,140
Total Services
119,898
Medicare Billing
$2.1M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 11,800 | $2.3M | $512,147 | 22.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 5,040 | $408,912 | $91,482 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 309 | 641 | $308,385 | $63,080 | 20.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 45 | 228 | $138,125 | $27,581 | 20.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 122 | 348 | $99,578 | $22,261 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 39 | $26,210 | $5,988 | 22.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 39 | $24,681 | $5,560 | 22.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 49 | $22,876 | $5,337 | 23.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 81 | 106 | $36,154 | $5,288 | 14.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $21,804 | $4,978 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $21,340 | $4,866 | 22.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 77 | $20,720 | $4,535 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 51 | $17,395 | $3,583 | 20.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 16 | 52 | $15,318 | $3,079 | 20.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 82 | $10,981 | $2,092 | 19.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 26 | 127 | $11,800 | $1,777 | 15.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 22 | 68 | $7,423 | $1,681 | 22.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 136 | $10,970 | $1,622 | 14.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 13 | 13 | $3,982 | $887.13 | 22.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 27 | $5,941 | $715.20 | 12.0% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 13 | 25 | $2,576 | $544.64 | 21.1% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 13 | 15 | $2,325 | $149.40 | 6.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 13 | 43 | $160.73 | $35.95 | 22.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 18 | 6,300 | $357,320 | $93,049 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 334 | 741 | $235,016 | $77,657 | 33.0% |
About Dr. Thomas Joseph, MD
Dr. Thomas Joseph, MD is a Hematology healthcare provider based in Santa Clarita, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861430092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Joseph, MD has received a total of $10,971 in payments from pharmaceutical and medical device companies, with $758.65 received in 2024. These payments were reported across 210 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($7,073).
As a Medicare-enrolled provider, Joseph has provided services to 5,140 Medicare beneficiaries, totaling 119,898 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Santa Clarita, CA
- Active Since 06/02/2006
- Last Updated 11/05/2020
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1861430092
Products in Payments
- IMFINZI (Drug) $2,890
- KEYTRUDA (Biological) $678.33
- OPDIVO (Biological) $467.54
- ADCETRIS (Biological) $309.27
- ZEJULA (Drug) $282.61
- SARCLISA (Biological) $242.63
- BRUKINSA (Drug) $220.41
- KYPHON Balloon Kyphoplasty (Device) $182.54
- XGEVA (Biological) $173.94
- Lenvima (Drug) $169.34
- COROFLOW (Device) $165.05
- XARELTO (Drug) $162.14
- CALQUENCE (Drug) $153.14
- Yescarta (Drug) $150.00
- Imbruvica (Drug) $147.31
- TECENTRIQ (Biological) $143.25
- SOLIQUA 100/33 (Biological) $138.88
- ELITEK (Drug) $135.53
- AYVAKIT (Drug) $129.21
- ARYMO ER (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.